leisure time -WSS

leisure time

author：focus 2025-09-06 01:59:10 - browse：778

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： VC firm General Catalyst wants to buy a health system

WSS

There’s a way to spot data fakery. All journals should be using it

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Why age limits for politicians are a terrible idea

hotspot

leisure time

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Was Amgen transparent enough on FDA's concern on cancer drug?

Dobbs anniversary: the lost opportunity of abortion as health care

FDA rejects Alnylam's heart disease treatment over insufficient data

New air purifier tech could be key to improving indoor air quality

When women are denied an abortion, their children fare worse than peers

Psychedelics group wrestles with new pharma identity

FDA rejects Alnylam's heart disease treatment over insufficient data

As demand for Covid shots wanes, Moderna seeks its next success

Are infertility treatments 'essential' during the Covid

focus

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Delta passengers in Vegas fall sick while waiting on flight in triple

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Sana to lay off nearly a third of staff, de

In rare move, senator releases unverified FBI source report alleging Biden bribe

FDA authorizes Novavax’s updated Covid

explore

focus

hotspot

explore